Akari Therapeutics Plc - 8-K Filing

Akari Therapeutics reports Q3 2026 results with $5.7M cash on hand and initiation of GLP toxicology studies for AKTX-101. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 22:21 UTC

Tickers: $AKTX

Read the full article at SEC EDGAR

More Regulatory news

BT Brands, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 22:32 UTC
MICROVISION, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 22:31 UTC
Fermi Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 22:29 UTC
Freenome, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 22:29 UTC
MEXCO ENERGY CORP - 8-K Filing SEC EDGAR · November 12, 2026, 22:28 UTC
SHF Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 22:28 UTC
SILVER BOW MINING CORP. - 10-Q Filing SEC EDGAR · November 12, 2026, 22:27 UTC
HOST HOTELS & RESORTS, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 22:27 UTC
LGL GROUP INC - 10-Q Filing SEC EDGAR · November 12, 2026, 22:27 UTC
Bright Mountain Media, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 22:27 UTC